Financial Tear Sheet

Corporate Profile

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. VALOR is Sunesis. Phase 3, randomized, double-blind, placebo-controlled, pivotal trial in patients with first relapsed or refractory AML. The trial is expected to enroll 450 evaluable patients at more than 100 leading sites in the U.S., Canada, Europe, Australia and New Zealand. The VALOR trial is currently enrolling patients, who are randomized one to one to receive either vosaroxin on days one and four in combination with cytarabine daily for five days, or placebo in combination with cytarabine. Additionally, the VALOR trial employs an innovative, adaptive trial design that allows for a one-time sample size adjustment by the DSMB at the interim analysis to maintain adequate power across a broader range of survival outcomes. The trial's primary endpoint is overall survival. For more information on the VALOR trial, please visit www.valortrial.com.

Stock Performance

SNSS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	$5.56
Change (%)	▲ 0.04 (0.72%)
Volume	122,880
52 Week Low	$2.30
Market Cap	$286,946,040
Rolling EPS	-0.84
PE Ratio	N/A
Shares Outstanding	51,609,000
Data as of 05/24/13 4:00 p.m. ET	

Recent Headlines & Events

05/10/13
Sunesis to Present at Upcoming Investor Conferences

05/09/13
Sunesis Pharmaceuticals Reports First Quarter Financial Results and Recent Highlights

05/02/13
Sunesis to Host Conference Call on May 9th to Discuss First Quarter Financial Results and Recent Highlights

There are currently no events scheduled.

Analyst Ratings

1-Strong Buy	4
2-Buy	5
3-Hold	0
4-Underperform	0
5-Sell	0

Mean Recommendation: 1.6



SEC Filings

Filing Date	Form
05/09/13	10-Q
05/09/13	8-K
05/01/13	ARS
04/30/13	EFFECT

Corporate Governance

Daniel N. Swisher, Jr.	Chief Executive Officer and President
Eric H. Bjerkholt	Executive Vice President, Corporate Development and Finance, Chief Financial Officer
Adam R. Craig, M.D., Ph.D., M.B.A	Executive Vice President, Development and Chief Medical Officer
Gene Jamieson	Vice President of Chemistry, Manufacturing and Controls (CMC)
Deborah A. Thomas, Ph.D.	Vice President, Regulatory Affairs and Medical Writing

Powered By EDGAR Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed